You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 8, 2025

Drug Price Trends for DOXYCYCLINE IR-DR


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for DOXYCYCLINE IR-DR

Average Pharmacy Cost for DOXYCYCLINE IR-DR

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
DOXYCYCLINE IR-DR 40 MG CAP 43598-0457-30 15.99195 EACH 2025-01-22
DOXYCYCLINE IR-DR 40 MG CAP 68308-0668-30 15.99195 EACH 2025-01-22
DOXYCYCLINE IR-DR 40 MG CAP 62332-0785-30 15.99195 EACH 2025-01-22
DOXYCYCLINE IR-DR 40 MG CAP 60505-4775-03 15.99195 EACH 2025-01-22
DOXYCYCLINE IR-DR 40 MG CAP 66993-0815-30 15.99195 EACH 2025-01-22
DOXYCYCLINE IR-DR 40 MG CAP 70748-0308-06 15.99195 EACH 2025-01-22
DOXYCYCLINE IR-DR 40 MG CAP 60505-4775-03 17.44155 EACH 2024-12-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Doxycycline IR-DR

Introduction to Doxycycline

Doxycycline is a tetracycline antibiotic widely used to treat various bacterial infections, including intestinal, respiratory, and urinary tract infections, as well as dermatological conditions like rosacea. It is available in several forms, including immediate-release (IR) and extended-release (ER) oral tablets, capsules, and liquid suspensions.

Market Size and Growth

The market for oral doxycycline hyclate is significant and growing. As of 2022, the market size was valued at USD 4.2 billion and is projected to grow from USD 4.6 billion in 2023 to USD 9.2 billion by 2032. This growth is driven by increasing demand for effective antibiotics and the expanding prevalence of bacterial infections[1].

Product Types and Applications

Doxycycline is available in various product types, including tablets, capsules, and oral suspensions. These products are used for a range of applications:

  • Intestinal Infections: Doxycycline is effective against infections such as those caused by E. coli and other gastrointestinal pathogens.
  • Respiratory Tract Infections: It is used to treat respiratory infections, including pneumonia and bronchitis.
  • Urinary Tract Infections: Doxycycline is prescribed for urinary tract infections, particularly those caused by E. coli and other bacteria.
  • Dermatological Conditions: It is also used to treat rosacea and acne, with formulations like Oracea being specifically designed for these conditions[5].

Distribution Channels

The distribution of doxycycline occurs through several channels:

  • Hospital Pharmacy: Often used for inpatient treatments.
  • Retail Pharmacy: Common for outpatient prescriptions.
  • Online Pharmacy: Increasingly popular due to convenience and sometimes lower prices[1].

Regional Market Analysis

The global market for doxycycline is segmented by region, with North America being one of the largest consumers. Other significant regions include Europe, Asia-Pacific, and the rest of the world. The demand in these regions is driven by the prevalence of bacterial infections and the availability of healthcare infrastructure[1][4].

Pricing and Cost Factors

The cost of doxycycline can vary significantly based on several factors:

  • Form and Strength: Different forms (capsules, tablets, liquid suspensions) and strengths (e.g., 50 mg, 100 mg) of doxycycline have different price points. For example, a 100 mg oral capsule can range from $1.03 to $1.19 per unit for a quantity of 30, while a 40 mg oral delayed-release capsule can cost between $21.52 and $26.93 per unit for a quantity of 30[2][5].

  • Treatment Plan: The duration and specifics of the treatment plan can influence the overall cost.

  • Insurance Coverage: The extent of insurance coverage can significantly affect the out-of-pocket cost for patients.

  • Pharmacy: Prices can vary between different pharmacies, including hospital pharmacies, retail pharmacies, and online pharmacies[5].

Price Projections

Given the growing demand and expanding market size, here are some key price projections:

  • Immediate-Release Tablets: Prices for immediate-release tablets are expected to remain relatively stable, with costs ranging from $1.50 to $2.00 per unit for common strengths like 50 mg and 100 mg.
  • Extended-Release Tablets: Extended-release formulations, such as the 50 mg and 75 mg tablets, may see slight increases in price due to their convenience and therapeutic benefits. For example, the 75 mg extended-release tablet could range from $2.59 to $5.52 per unit[2].

Competitive Landscape

The market for doxycycline is competitive, with several brand-name and generic versions available. For instance:

  • Oracea: A brand-name extended-release capsule specifically designed for treating rosacea.
  • Doryx: Another brand-name extended-release tablet.
  • Generic Versions: Numerous generic versions are available, which often offer more affordable options for patients[5].

Emerging Trends and Developments

  • Modified-Release Formulations: New formulations like DFD-29, a modified-release minocycline hydrochloride capsule, are being developed to offer better dermal concentrations and therapeutic outcomes. These formulations may compete with doxycycline in certain indications, such as rosacea[3].

Regulatory Environment

The regulatory environment plays a crucial role in the pricing and availability of doxycycline. New Drug Applications (NDAs) and approvals by regulatory bodies like the FDA can impact the market dynamics. For example, the upcoming PDUFA date for DFD-29 in November 2024 could influence the competitive landscape for rosacea treatments[3].

Key Takeaways

  • Growing Market: The oral doxycycline hyclate market is projected to grow significantly by 2032.
  • Variable Pricing: Prices vary based on form, strength, treatment plan, insurance coverage, and pharmacy.
  • Regional Demand: North America is a major consumer, with other regions also showing significant demand.
  • Competitive Landscape: Multiple brand-name and generic versions are available, with emerging trends in modified-release formulations.
  • Regulatory Impact: Regulatory approvals and new drug applications can influence market dynamics.

FAQs

Q: What is the current market size of the oral doxycycline hyclate market?

A: The market size was valued at USD 4.2 billion in 2022 and is projected to grow to USD 9.2 billion by 2032[1].

Q: What are the main factors that affect the price of doxycycline?

A: The price of doxycycline can vary based on the form and strength of the medication, treatment plan, insurance coverage, and the pharmacy used[5].

Q: Which regions are the largest consumers of doxycycline?

A: North America is one of the largest consumers, followed by Europe, Asia-Pacific, and the rest of the world[1][4].

Q: Are there any new formulations or drugs that could compete with doxycycline?

A: Yes, formulations like DFD-29, a modified-release minocycline hydrochloride capsule, are being developed and could compete with doxycycline in certain indications[3].

Q: How does the regulatory environment impact the market for doxycycline?

A: Regulatory approvals and new drug applications can influence the availability and pricing of doxycycline, as well as introduce new competitors into the market[3].

Sources

  1. Market Research Future, "Oral Doxycycline Hyclate Market Size, Trends, Report 2032".
  2. Drugs.com, "Doxycycline Prices, Coupons, Copay Cards & Patient Assistance".
  3. Journey Medical Corporation, "Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference".
  4. ChemAnalyst, "Doxycycline Hydrochloride Market Size, Share & Forecast 2034".
  5. Medical News Today, "Doxycycline cost 2024: Coupons and more".

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.